Pharmaceutical Commerce - February 2022 Issue (PDF)

Specialty distribution and provider platforms drove September-quarter profit gains at the Big Three as brand pricing weighed on results.

Siloed pricing, contracting and affordability decisions can undercut a launch. IQVIA experts explain how system-level modeling surfaces trade-offs early.

In this week’s Pharma Pulse, CVS Health plans to separate into two public companies, Bayer weighs what MFN pricing could mean for its launch strategies and an ACTO survey finds most life sciences leaders see no clear industry standard for responsible AI.

Accessia Health’s Tiara Green says Part D reforms eased drug costs, but premiums, deductibles and payer policies still limit patient access.

ELPRO CEO Frederik Dresen explains how cold chain monitoring moved from compliance to risk management, and what biologics and advanced therapies demand.

Inizio Ignite leaders argue static, milestone-driven launch plans fall short and AI sharpens execution only when built on a sound strategy.

Foreign-trade zones allow pharma companies to hold imported inventory closer to U.S. demand while deferring duties and keeping market allocation open.

Octapharma USA's Kerem Tokel, a LogiPharma USA 2026 freight security panelist, discusses theft hotspots, the export of stolen pharmaceutical loads and how to tighten chain of custody.